Targeting Mycobacterium tuberculosis CoaBC through chemical inhibition of 4′-phosphopantothenoyl- l -cysteine synthetase (CoaB) activity

Targeting Mycobacterium tuberculosis CoaBC through chemical inhibition of 4′-phosphopantothenoyl- l -cysteine synthetase (CoaB) activity. Evans, J. C., Murugesan, D., Post, J. M, Mendes, V., Wang, Z., Nahiyaan, N., Lynch, S. L, Thompson, S., Green, S. R, Ray, P. C, Hess, J., Spry, C., Coyne, A. G, Abell, C., Boshoff, H. I M, Wyatt, P. G, Rhee, K. Y, Blundell, T. L, Barry, C. E, & Mizrahi, V. ACS Infectious Diseases, 7(6):1666–1679, American Chemical Society, may, 2021.

Paper doi abstract bibtex

Coenzyme A (CoA) is a ubiquitous cofactor present in all living cells and estimated to be required for up to 9% of intracellular enzymatic reactions. Mycobacterium tuberculosis (Mtb) relies on its own ability to biosynthesize CoA to meet the needs of the myriad enzymatic reactions that depend on this cofactor for activity. As such, the pathway to CoA biosynthesis is recognized as a potential source of novel tuberculosis drug targets. In prior work, we genetically validated CoaBC as a bactericidal drug target in Mtb in vitro and in vivo. Here, we describe the identification of compound 1f, a small molecule inhibitor of the 4′-phosphopantothenoyl-L-cysteine synthetase (PPCS; CoaB) domain of the bifunctional Mtb CoaBC, and show that this compound displays on-target activity in Mtb. Compound 1f was found to inhibit CoaBC uncompetitively with respect to 4′-phosphopantothenate, the substrate for the CoaB-catalyzed reaction. Furthermore, metabolomic profiling of wild-type Mtb H37Rv following exposure to compound 1f produced a signature consistent with perturbations in pantothenate and CoA biosynthesis. As the first report of a direct small molecule inhibitor of Mtb CoaBC displaying target-selective whole-cell activity, this study confirms the druggability of CoaBC and chemically validates this target.

@article{Evans2021,
abstract = {Coenzyme A (CoA) is a ubiquitous cofactor present in all living cells and estimated to be required for up to 9{\%} of intracellular enzymatic reactions. Mycobacterium tuberculosis (Mtb) relies on its own ability to biosynthesize CoA to meet the needs of the myriad enzymatic reactions that depend on this cofactor for activity. As such, the pathway to CoA biosynthesis is recognized as a potential source of novel tuberculosis drug targets. In prior work, we genetically validated CoaBC as a bactericidal drug target in Mtb in vitro and in vivo. Here, we describe the identification of compound 1f, a small molecule inhibitor of the 4′-phosphopantothenoyl-L-cysteine synthetase (PPCS; CoaB) domain of the bifunctional Mtb CoaBC, and show that this compound displays on-target activity in Mtb. Compound 1f was found to inhibit CoaBC uncompetitively with respect to 4′-phosphopantothenate, the substrate for the CoaB-catalyzed reaction. Furthermore, metabolomic profiling of wild-type Mtb H37Rv following exposure to compound 1f produced a signature consistent with perturbations in pantothenate and CoA biosynthesis. As the first report of a direct small molecule inhibitor of Mtb CoaBC displaying target-selective whole-cell activity, this study confirms the druggability of CoaBC and chemically validates this target.},
author = {Evans, Joanna C. and Murugesan, Dinakaran and Post, John M and Mendes, Vitor and Wang, Zhe and Nahiyaan, Navid and Lynch, Sasha L and Thompson, Stephen and Green, Simon R and Ray, Peter C and Hess, Jeannine and Spry, Christina and Coyne, Anthony G and Abell, Chris and Boshoff, Helena I M and Wyatt, Paul G and Rhee, Kyu Y and Blundell, Tom L and Barry, Clifton E and Mizrahi, Valerie},
doi = {10.1021/acsinfecdis.0c00904},
file = {:C$\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Evans et al. - 2021 - Targeting iMycobacterium tuberculosisi CoaBC through chemical inhibition of 4′-phosphopantothenoyl- l -cysteine sy.pdf:pdf},
issn = {2373-8227},
journal = {ACS Infectious Diseases},
keywords = {CoaBC,OA,coenzyme A,drug discovery,fund{\_}not{\_}ack,original,tuberculosis},
mendeley-tags = {OA,fund{\_}not{\_}ack,original},
month = {may},
number = {6},
pages = {1666--1679},
pmid = {33939919},
publisher = {American Chemical Society},
title = {{Targeting \textit{Mycobacterium tuberculosis} CoaBC through chemical inhibition of 4′-phosphopantothenoyl- l -cysteine synthetase (CoaB) activity}},
url = {https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00904},
volume = {7},
year = {2021}
}

Downloads: 0

{"_id":"29wLHvs336morvsvp","bibbaseid":"evans-murugesan-post-mendes-wang-nahiyaan-lynch-thompson-etal-targetingimycobacteriumtuberculosisicoabcthroughchemicalinhibitionof4phosphopantothenoyllcysteinesynthetasecoabactivity-2021","author_short":["Evans, J. C.","Murugesan, D.","Post, J. M","Mendes, V.","Wang, Z.","Nahiyaan, N.","Lynch, S. L","Thompson, S.","Green, S. R","Ray, P. C","Hess, J.","Spry, C.","Coyne, A. G","Abell, C.","Boshoff, H. I M","Wyatt, P. G","Rhee, K. Y","Blundell, T. L","Barry, C. E","Mizrahi, V."],"bibdata":{"bibtype":"article","type":"article","abstract":"Coenzyme A (CoA) is a ubiquitous cofactor present in all living cells and estimated to be required for up to 9% of intracellular enzymatic reactions. Mycobacterium tuberculosis (Mtb) relies on its own ability to biosynthesize CoA to meet the needs of the myriad enzymatic reactions that depend on this cofactor for activity. As such, the pathway to CoA biosynthesis is recognized as a potential source of novel tuberculosis drug targets. In prior work, we genetically validated CoaBC as a bactericidal drug target in Mtb in vitro and in vivo. Here, we describe the identification of compound 1f, a small molecule inhibitor of the 4′-phosphopantothenoyl-L-cysteine synthetase (PPCS; CoaB) domain of the bifunctional Mtb CoaBC, and show that this compound displays on-target activity in Mtb. Compound 1f was found to inhibit CoaBC uncompetitively with respect to 4′-phosphopantothenate, the substrate for the CoaB-catalyzed reaction. Furthermore, metabolomic profiling of wild-type Mtb H37Rv following exposure to compound 1f produced a signature consistent with perturbations in pantothenate and CoA biosynthesis. As the first report of a direct small molecule inhibitor of Mtb CoaBC displaying target-selective whole-cell activity, this study confirms the druggability of CoaBC and chemically validates this target.","author":[{"propositions":[],"lastnames":["Evans"],"firstnames":["Joanna","C."],"suffixes":[]},{"propositions":[],"lastnames":["Murugesan"],"firstnames":["Dinakaran"],"suffixes":[]},{"propositions":[],"lastnames":["Post"],"firstnames":["John","M"],"suffixes":[]},{"propositions":[],"lastnames":["Mendes"],"firstnames":["Vitor"],"suffixes":[]},{"propositions":[],"lastnames":["Wang"],"firstnames":["Zhe"],"suffixes":[]},{"propositions":[],"lastnames":["Nahiyaan"],"firstnames":["Navid"],"suffixes":[]},{"propositions":[],"lastnames":["Lynch"],"firstnames":["Sasha","L"],"suffixes":[]},{"propositions":[],"lastnames":["Thompson"],"firstnames":["Stephen"],"suffixes":[]},{"propositions":[],"lastnames":["Green"],"firstnames":["Simon","R"],"suffixes":[]},{"propositions":[],"lastnames":["Ray"],"firstnames":["Peter","C"],"suffixes":[]},{"propositions":[],"lastnames":["Hess"],"firstnames":["Jeannine"],"suffixes":[]},{"propositions":[],"lastnames":["Spry"],"firstnames":["Christina"],"suffixes":[]},{"propositions":[],"lastnames":["Coyne"],"firstnames":["Anthony","G"],"suffixes":[]},{"propositions":[],"lastnames":["Abell"],"firstnames":["Chris"],"suffixes":[]},{"propositions":[],"lastnames":["Boshoff"],"firstnames":["Helena","I","M"],"suffixes":[]},{"propositions":[],"lastnames":["Wyatt"],"firstnames":["Paul","G"],"suffixes":[]},{"propositions":[],"lastnames":["Rhee"],"firstnames":["Kyu","Y"],"suffixes":[]},{"propositions":[],"lastnames":["Blundell"],"firstnames":["Tom","L"],"suffixes":[]},{"propositions":[],"lastnames":["Barry"],"firstnames":["Clifton","E"],"suffixes":[]},{"propositions":[],"lastnames":["Mizrahi"],"firstnames":["Valerie"],"suffixes":[]}],"doi":"10.1021/acsinfecdis.0c00904","file":":C$\\$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Evans et al. - 2021 - Targeting iMycobacterium tuberculosisi CoaBC through chemical inhibition of 4′-phosphopantothenoyl- l -cysteine sy.pdf:pdf","issn":"2373-8227","journal":"ACS Infectious Diseases","keywords":"CoaBC,OA,coenzyme A,drug discovery,fund_not_ack,original,tuberculosis","mendeley-tags":"OA,fund_not_ack,original","month":"may","number":"6","pages":"1666–1679","pmid":"33939919","publisher":"American Chemical Society","title":"Targeting Mycobacterium tuberculosis CoaBC through chemical inhibition of 4′-phosphopantothenoyl- l -cysteine synthetase (CoaB) activity","url":"https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00904","volume":"7","year":"2021","bibtex":"@article{Evans2021,\r\nabstract = {Coenzyme A (CoA) is a ubiquitous cofactor present in all living cells and estimated to be required for up to 9{\\%} of intracellular enzymatic reactions. Mycobacterium tuberculosis (Mtb) relies on its own ability to biosynthesize CoA to meet the needs of the myriad enzymatic reactions that depend on this cofactor for activity. As such, the pathway to CoA biosynthesis is recognized as a potential source of novel tuberculosis drug targets. In prior work, we genetically validated CoaBC as a bactericidal drug target in Mtb in vitro and in vivo. Here, we describe the identification of compound 1f, a small molecule inhibitor of the 4′-phosphopantothenoyl-L-cysteine synthetase (PPCS; CoaB) domain of the bifunctional Mtb CoaBC, and show that this compound displays on-target activity in Mtb. Compound 1f was found to inhibit CoaBC uncompetitively with respect to 4′-phosphopantothenate, the substrate for the CoaB-catalyzed reaction. Furthermore, metabolomic profiling of wild-type Mtb H37Rv following exposure to compound 1f produced a signature consistent with perturbations in pantothenate and CoA biosynthesis. As the first report of a direct small molecule inhibitor of Mtb CoaBC displaying target-selective whole-cell activity, this study confirms the druggability of CoaBC and chemically validates this target.},\r\nauthor = {Evans, Joanna C. and Murugesan, Dinakaran and Post, John M and Mendes, Vitor and Wang, Zhe and Nahiyaan, Navid and Lynch, Sasha L and Thompson, Stephen and Green, Simon R and Ray, Peter C and Hess, Jeannine and Spry, Christina and Coyne, Anthony G and Abell, Chris and Boshoff, Helena I M and Wyatt, Paul G and Rhee, Kyu Y and Blundell, Tom L and Barry, Clifton E and Mizrahi, Valerie},\r\ndoi = {10.1021/acsinfecdis.0c00904},\r\nfile = {:C$\\backslash$:/Users/01462563/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Evans et al. - 2021 - Targeting iMycobacterium tuberculosisi CoaBC through chemical inhibition of 4′-phosphopantothenoyl- l -cysteine sy.pdf:pdf},\r\nissn = {2373-8227},\r\njournal = {ACS Infectious Diseases},\r\nkeywords = {CoaBC,OA,coenzyme A,drug discovery,fund{\\_}not{\\_}ack,original,tuberculosis},\r\nmendeley-tags = {OA,fund{\\_}not{\\_}ack,original},\r\nmonth = {may},\r\nnumber = {6},\r\npages = {1666--1679},\r\npmid = {33939919},\r\npublisher = {American Chemical Society},\r\ntitle = {{Targeting \\textit{Mycobacterium tuberculosis} CoaBC through chemical inhibition of 4′-phosphopantothenoyl- l -cysteine synthetase (CoaB) activity}},\r\nurl = {https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00904},\r\nvolume = {7},\r\nyear = {2021}\r\n}\r\n","author_short":["Evans, J. C.","Murugesan, D.","Post, J. M","Mendes, V.","Wang, Z.","Nahiyaan, N.","Lynch, S. L","Thompson, S.","Green, S. R","Ray, P. C","Hess, J.","Spry, C.","Coyne, A. G","Abell, C.","Boshoff, H. I M","Wyatt, P. G","Rhee, K. Y","Blundell, T. L","Barry, C. E","Mizrahi, V."],"key":"Evans2021","id":"Evans2021","bibbaseid":"evans-murugesan-post-mendes-wang-nahiyaan-lynch-thompson-etal-targetingimycobacteriumtuberculosisicoabcthroughchemicalinhibitionof4phosphopantothenoyllcysteinesynthetasecoabactivity-2021","role":"author","urls":{"Paper":"https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00904"},"keyword":["CoaBC","OA","coenzyme A","drug discovery","fund_not_ack","original","tuberculosis"],"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-JLqZ7RwZ3VC2d6ErLGHAtOeMRS_7GCz","dataSources":["Krmt6gt9ktB2s6ARh"],"keywords":["coabc","oa","coenzyme a","drug discovery","fund_not_ack","original","tuberculosis"],"search_terms":["targeting","mycobacterium","tuberculosis","coabc","through","chemical","inhibition","phosphopantothenoyl","cysteine","synthetase","coab","activity","evans","murugesan","post","mendes","wang","nahiyaan","lynch","thompson","green","ray","hess","spry","coyne","abell","boshoff","wyatt","rhee","blundell","barry","mizrahi"],"title":"Targeting Mycobacterium tuberculosis CoaBC through chemical inhibition of 4′-phosphopantothenoyl- l -cysteine synthetase (CoaB) activity","year":2021}